Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer

Схожі ресурси

• Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
  за авторством: Dennis C. Sgroi, та інші
  Опубліковано: (2022-12-01)
• An Extraordinary New Toad (Bufo) ttom Costa Rica
  за авторством: Jay M Savage
  Опубліковано: (2002-06-01)
• Tamoxifen-independent recombination in the RIP-CreER mouse.
  за авторством: Yanmei Liu, та інші
  Опубліковано: (2010-10-01)
• Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals
  за авторством: Joonatan Palmu, та інші
  Опубліковано: (2020-08-01)
• FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
  за авторством: Qing Lv MD, PhD, та інші
  Опубліковано: (2021-03-01)